John Cox Sells 3,311 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 3,311 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total transaction of $60,789.96. Following the completion of the transaction, the chief executive officer directly owned 370,834 shares of the company’s stock, valued at approximately $6,808,512.24. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Down 5.4%

Shares of NASDAQ:DYN opened at $17.29 on Friday. The firm has a fifty day moving average price of $18.34 and a two-hundred day moving average price of $18.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 22.25. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -5.37 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the prior year, the company earned ($1.05) earnings per share. Analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DYN shares. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. HC Wainwright lowered their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Sanford C. Bernstein raised their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. raised its position in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Vanguard Group Inc. raised its position in Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after purchasing an additional 1,455,151 shares during the period. State Street Corp raised its position in Dyne Therapeutics by 27.0% in the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after purchasing an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Dyne Therapeutics by 45.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after purchasing an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd purchased a new position in Dyne Therapeutics in the 4th quarter worth $93,926,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
• Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
• Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.